Latest Research, Industry, Medical and Scientific News
Zida LLC Recently Launched The Zida Control Sock to Help People Fight Against Incontinence
Zida has recently launched “The Zida Control Sock” to help individuals suffering from overactive bladder and incontinence reduce their symptoms. The Zida Control Sock is an FDA-cleared neuromodulation device that uses transcutaneous tibial nerve stimulation to treat overactive bladder and incontinence. Read more.
Source: Newsfile Corp., January 11, 2023
Cellf BIO Begins Phase 1 Clinical Trial of BioSphincter™ Implant for Fecal Incontinence
Cellf BIO, a biotechnology company that manufactures bioengineered sphincters using autologous progenitor cells, announced today that it has begun its Phase 1 clinical trial for its BioSphincter™ Implant for the treatment of severe passive fecal incontinence (FI). The FDA cleared the company’s Investigational New Drug (IND) application, and the Institutional Review Board (IRB) approved the trial to begin enrolling participants. Read more.
Source: Globe Newswire, January 5, 2023
Does What You Drink Affect Your Risk of Urinary Incontinence?
Urinary incontinence affects nearly 20% of women aged older than 50 years. Many factors can influence a woman’s risk of urinary incontinence. A new study suggests that despite some commonly held misconceptions, the consumption of artificially sweetened beverages does not have a significant effect on a woman’s likelihood of developing the condition. Study results are published online today in Menopause, the journal of The North American Menopause Society (NAMS). Read more.
Source: Newswise, December 14, 2022
Weight-loss Surgery May Relieve Urinary Incontinence
Weight-loss surgery can have many health benefits, and now a new study suggests that long-term relief from urinary incontinence is one of them. Urinary incontinence (UI) is a common problem, and obesity is among the risk factors for it: Extra pounds put more pressure on the bladder and the muscles supporting it, which can cause urine to leak. Read more.
Source: UPI, December 14, 2022
Myrbetriq Plus Pelvic Floor Exercises Fail to Ease Overactive Bladder
Combining Myrbetriq (mirabegron) with modifications like pelvic floor exercises failed to ease overactive bladder symptoms in people with Parkinson’s disease in a pilot clinical trial, the study’s main goal. But the treatment, approved for overactive bladder, when used with such behavioral modifications did increase the amount of urine patients were able to expel with each urination, relative to patients using only pelvic floor exercise. But this benefit was temporary. Read more.
Source: Parkinson’s News Today, December 7, 2022
Symptomatic Covid-19 Infection Is Associated With An Increased Risk Of Overactive Bladder Symptoms
A new study finds that symptomatic Covid-19 infection is associated with the risk of developing or exacerbating overactive bladder symptoms. As an overlooked area of study, only a handful of investigations have focused on the impact of Covid-19 infection on the urinary system. Previous studies have found increased urinary tract symptoms, including the frequency, urgency, and waking up to urinate, post Covid-19 infection; they attributed the symptoms to inflammation and described the condition as Covid-Associated Cystitis (CAC). Read more.
Source: Forbes, December 5, 2022